Details for Patent: 11,878,049
Summary for Patent: 11,878,049
| Title: | Mitapivat therapy and modulators of cytochrome P450 |
| Abstract: | Described herein are methods of treating pyruvate kinase deficiency (PKD), sickle cell disease or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof, or use of the drug for the treatment of these conditions, in combination with or in the absence of with a secondary drug, such as an inducer or an inhibitor of cytochrome P450. Various doses and dosing regimens of mitapivat in monotherapy and in concomitant medications are described. |
| Inventor(s): | Varsha Venkatachalam Iyer, Chandra Agarwal Prakash, Hua Yang |
| Assignee: | Agios Pharmaceuticals Inc |
| Application Number: | US16/900,610 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,878,049 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,878,049
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | AQVESME | mitapivat sulfate | TABLET;ORAL | 216196-004 | Dec 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR USING A PYRUVATE KINASE ACTIVATOR TO MITIGATE DRUG INTERACTIONS IN ADULTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Start Trial | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Start Trial | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Start Trial | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
